--- title: "Pre-market Trend | KalVista Pharma (KALV) surged nearly 40% on 4/29, can the capital frenzy continue?" type: "News" locale: "en" url: "https://longbridge.com/en/news/284639461.md" description: "Yesterday's closing, KalVista Pharma's stock price soared 38.62%, closing at $26.67, with an intraday high of $26.76 and a trading volume reaching $1.904 billion, showing several times the average daily level. The MACD daily line formed a bullish signal above the zero axis, combined with such a fierce influx of funds, indicating a typical event-driven violent surge in the technical aspect. Such a huge trading volume means that large-scale funds are actively involved, and market sentiment is in an extremely euphoric state. From the news perspective, the activity level of funds in the biotechnology sector significantly increased yesterday, and KalVista, as a biopharmaceutical company focused on rare diseases such as hereditary angioedema, is likely to have surged due to major clinical progress or collaboration news. The biotechnology sector has frequently seen event-driven market trends recently, and the market is highly sensitive to breakthroughs in innovative drug pipelines. Against the macro backdrop of the Federal Reserve maintaining interest rates, high beta biotechnology stocks often become the focus of speculative funds. From a technical perspective, a nearly 40% increase in a single day indicates that short-term profit-taking has become very substantial, and the stock price has significantly deviated from the short-term moving average system, placing the technical aspect in a severely overbought area. Today, it is crucial to closely monitor whether there are sustained positive news to support the price; if there are no new catalysts, the probability of significant fluctuations or even a rapid pullback during the day is not low. The area around $19 (yesterday's opening range) can be seen as the first reference area for a pullback" datetime: "2026-04-30T13:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284639461.md) - [en](https://longbridge.com/en/news/284639461.md) - [zh-HK](https://longbridge.com/zh-HK/news/284639461.md) --- # Pre-market Trend | KalVista Pharma (KALV) surged nearly 40% on 4/29, can the capital frenzy continue? Yesterday, KalVista Pharma's stock price soared by 38.62%, closing at $26.67, with an intraday high of $26.76 and a trading volume reaching $1.904 billion, showing several times the average daily level. The MACD daily line formed a bullish signal above the zero axis, combined with such a fierce influx of funds, indicating a typical event-driven violent surge in the technical aspect. Such a huge trading volume suggests that large-scale funds are actively intervening, and market sentiment is in an extremely euphoric state. From the news perspective, the activity level of funds in the biotechnology sector significantly increased yesterday. KalVista, as a biopharmaceutical company focused on rare diseases such as hereditary angioedema, likely experienced this surge due to significant clinical progress or collaboration news. The biotechnology sector has recently frequently seen event-driven market trends, and the market is highly sensitive to breakthroughs in innovative drug pipelines. Against the macro backdrop of the Federal Reserve maintaining interest rates, high-beta biotechnology stocks often become a key focus for speculative funds. From a technical perspective, a nearly 40% increase in a single day indicates that short-term profit-taking has become very substantial, and the stock price has significantly deviated from the short-term moving average system, placing the technical aspect in a severely overbought region. Today, it is crucial to closely monitor whether there are sustained positive news to support the price; if there are no new catalysts, the probability of significant fluctuations or even a rapid pullback during the day is not low. The area around $19 (the opening area yesterday) can be seen as the first reference area for a pullback. In the short term, although the explosive power is astonishing, the sustainability of the event-driven market in biotechnology stocks highly depends on subsequent news. The risk of chasing high prices is enormous, and volatility may further amplify today; investors should fully recognize the high volatility characteristics of such targets. _This article only provides technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances._ ### Related Stocks - [KALV.US](https://longbridge.com/en/quote/KALV.US.md) ## Related News & Research - [Merger Agreement With Chiesi Puts Strategic Handcuffs on KalVista, Raising Execution and Liquidity Risks](https://longbridge.com/en/news/286635514.md) - [Full Transcript: DRI HEALTHCARE TRUST Q1 2026 Earnings Call](https://longbridge.com/en/news/286578500.md) - [A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data](https://longbridge.com/en/news/286722721.md) - [Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion](https://longbridge.com/en/news/284552649.md) - [Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio | KALV Stock News](https://longbridge.com/en/news/284562776.md)